Hims & Hers enters Canadian market with a digital weight loss program leveraging generic semaglutide, signaling increased competition and accessibility in the growing GLP-1 and obesity treatment sector.

Learn about the rising cases of semaglutide overdose reported by American Poison Centers and the growing use of weight loss medications like Ozempic® and Wegovy®. Understand the risks associated with these drugs, initially developed for type 2 diabetes but now popular for weight loss.